Clearside Biomedical announced that its board of directors appointed George Lasezkay to be the company's interim chief executive officer, effective immediately. Lasezkay, a current member of the Clearside board of directors, succeeds Daniel White, who resigned as president and CEO and as a member of the Board of Directors to pursue other opportunities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 USD | +2.52% | -12.86% | +4.27% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 91.17M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical Announces Management Changes